LYTIR

Company · ALKS

Alkermes plc

Name as listed on its exchange; filed with the SEC as Alkermes plc.

Nasdaq's symbol directory lists ALKS on Nasdaq as “Alkermes plc - Ordinary Shares”.

In the 12 months to Nov 8, 2026: insiders sold on 10 occasions ($4.4M); 2 planned-sale notices; 2 congressional trade disclosures; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $4.4M in total.Jul: Insider sales $574KAug: Insider sales $3.1MSep: Insider sales $521KOct: Insider sales $83KNov: Insider sales $94KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $4.4M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Nancy lynn M. Snyderman sold on 1 day latest Aug 3, 2026 sold $2.2M
  2. Craig C. Hopkinson, EVP R&D, Chief Medical Officer sold on 3 days all under a 10b5-1 plan latest Sep 1, 2026 sold $1.3M
  3. Gaffin David Joseph, EVP, CLO, Alkermes, Inc. sold on 5 days all under a 10b5-1 plan latest Nov 3, 2026 sold $484K
  4. Nichols Christian Todd, SVP, Chief Commercial Officer sold on 1 day all under a 10b5-1 plan latest Aug 17, 2026 sold $373K
Every trade (10)
  1. SELLGaffin David Joseph, EVP, CLO, Alkermes, Inc. sold Nov 3, 2026 2,035 shares 10b5-1 plan (scheduled) filing $94K
  2. SELLGaffin David Joseph, EVP, CLO, Alkermes, Inc. sold Oct 2, 2026 2,034 shares 10b5-1 plan (scheduled) filing $83K
  3. SELLGaffin David Joseph, EVP, CLO, Alkermes, Inc. sold Sep 3, 2026 2,034 shares 10b5-1 plan (scheduled) filing $98K
  4. SELLCraig C. Hopkinson, EVP R&D, Chief Medical Officer sold Sep 1, 2026 9,000 shares 10b5-1 plan (scheduled) filing $423K
  5. SELLNichols Christian Todd, SVP, Chief Commercial Officer sold Aug 17, 2026 7,576 shares 2 legs combined 10b5-1 plan (scheduled) filing $373K
  6. SELLNancy lynn M. Snyderman sold Aug 3, 2026 44,472 shares filing $2.2M
  7. SELLCraig C. Hopkinson, EVP R&D, Chief Medical Officer sold Aug 3, 2026 9,000 shares 10b5-1 plan (scheduled) filing $437K
  8. SELLGaffin David Joseph, EVP, CLO, Alkermes, Inc. sold Aug 3, 2026 2,034 shares 10b5-1 plan (scheduled) filing $99K
  9. SELLGaffin David Joseph, EVP, CLO, Alkermes, Inc. sold Jul 6, 2026 2,034 shares 10b5-1 plan (scheduled) filing $110K
  10. SELLCraig C. Hopkinson, EVP R&D, Chief Medical Officer sold Jul 1, 2026 9,000 shares 2 legs combined 10b5-1 plan (scheduled) filing $464K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. Gaffin David Joseph filed Nov 3, 2026 Officer 2,035 shares planned sale date 11/03/2026 filing $94K
  2. Gaffin David Joseph filed Oct 2, 2026 Officer 2,034 shares planned sale date 10/02/2026 filing $83K

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Purchase Sep 29, 2026 reported Oct 12, 2026 one of 57 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Gilbert Cisneros (D-CA31): Purchase Jul 30, 2026 reported Sep 4, 2026 one of 66 trades the member reported that day House Stocks (including ADRs) $15,001 - $50,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 3, 2026
  2. Regulation FD disclosure; Other events filing Sep 21, 2026
  3. Departure or appointment of directors or officers; Regulation FD disclosure filing Sep 16, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.